Man-made chemicals which mimic oestrogen contribute to breast cancer

Health campaigners are urging politicians to act on the growing body of scientific evidence that links exposure to certain chemicals to spiralling rates of breast cancer. Scientists have known for decades that a woman's risk of developing breast cancer is influenced both by the levels of oestrogen produced by her own body and her use of drugs containing man-made oestrogens, such as hormone replacement therapy (HRT).

Now a new report, "Breast cancer and exposure to hormonally active chemicals", highlights the role of manmade chemicals which act like hormones in the development of breast cancer. The report, which was commissioned by the Health and Environment Alliance (HEAL) and CHEM Trust, was presented to Members of the European Parliament in Brussels on 2 April.

"Good laboratory and epidemiological evidence exists suggesting that man-made chemicals which mimic oestrogen contribute to breast cancer," stated the report's author, Professor Andreas Kortenkamp of the University of London's School of Pharmacy. "We will not be able to reduce the risk of breast cancer without addressing preventable causes, particularly exposure to chemicals."

Cases of breast cancer are on the rise across Europe, and over a million cases are diagnosed worldwide every year. "Although late age at first child birth and genetics are shown to contribute to the increase in breast cancer, the sheer number of newly diagnosed cases cannot solely be explained by these factors," the report reads. "Evidence is emerging that environmental influences, including chemical exposure, also play a role."

At the launch of the report, Professor Kortenkamp presented evidence showing that while low levels of individual chemicals have no discernible impact on breast cancer, when mixtures of chemicals are considered together, they have a clear impact, even when the level of each individual chemical is very low.

Professor Kortenkamp also highlighted the importance of exposure levels at different times in a woman's life; women are particularly vulnerable to elevated oestrogen levels in the womb, when the breast tissue is laid down, and at puberty, when the breasts' ductal system grows.

For example, research shows that women who were exposed to the pesticide DDT during puberty are more likely to develop breast cancer than women who were exposed to it later in life, when their breast tissue was less vulnerable.

Meanwhile another study focussed on women whose mothers took the drug DES (diethylstilboestrol) to avoid miscarriages, and so were exposed to synthetic oestrogens in the womb. The results revealed that these women face a doubled risk of developing breast cancer.

The list of chemicals which act like hormones, and the products containing them, is long. Some of these chemicals, including DDT and some other pesticides, are already banned. However, there are many more, including bisphenol A (BPA), which is found in plastic food storage containers; parabens, which are used in cosmetics; UV-filters from sunscreens and alkylphenols, which are found in plastics, paints, inks and detergents.

Scientists and health campaigners argue that as these chemicals are found in such a wide range of products, it is impossible for women to avoid exposure to them. The time is therefore ripe for regulators to take action to remove these chemicals from the environment, they say.

As Professor Kortenkamp pointed out, the European Union has funded a lot of excellent research on this subject. However, "this is not entirely matched by an equally well founded and well thought out regulatory approach to complement this, to act on the basis of scientific evidence," he told CORDIS News.

Meanwhile more research is needed. "We need to do more epidemiological studies to find out why women get breast cancer - how do they differ from the ones who don't get breast cancer," said Dr Annie Sasco, Team Leader for Epidemiology for Cancer Prevention at the French National Institute for Health and Medical Research (INSERM).

Doing these studies will require the use of biological markers to determine which products people have been exposed to. Toxicological studies and experimental studies in animals are also needed, Dr Sasco added.

"The efforts to screen for oestrogen-like chemicals need to be redoubled," said Professor Kortenkamp. "We are far from having a complete picture about this."

For more information, please visit:
http://www.chemicalshealthmonitor.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...